Advertisement
Screener

ALDEYRA THERAPEUTICS, INC. (ALDX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

2.3 / 5 stars · 18/40 Roast Me

ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 1.32 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06

  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 1.01M shares, a 786.33% increase year-over-year.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 303.17K shares, a 125.42% increase year-over-year.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 0.00 shares.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 248.82K shares, a 38.31% increase from fiscal 2024.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 179.90K shares, a 78.39% increase from fiscal 2023.
  • ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 100.84K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month
2026-06-301.01M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
1.32M shares
10-Q · filed 2026-08-06
1.32M shares
derived: sum of 3 quarters · filed 2026-08-06
1.32M shares
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31303.17K shares
10-Q · filed 2026-05-07
303.17K shares
derived: sum of 2 quarters · filed 2026-05-07
303.17K shares
derived: sum of 3 quarters · filed 2026-05-07
417.50K shares
derived: sum of 4 quarters · filed 2026-05-07
2025-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
0.00 shares
derived: sum of 2 quarters · filed 2026-02-27
114.33K shares
derived: sum of 3 quarters · filed 2026-02-27
248.82K shares
10-K · filed 2026-02-27
2025-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
114.33K shares
derived: sum of 2 quarters · filed 2025-11-05
248.82K shares
10-Q · filed 2025-11-05
248.82K shares
derived: sum of 4 quarters · filed 2025-11-05
2025-06-30114.33K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
248.82K shares
10-Q · filed 2025-08-07
248.82K shares
derived: sum of 3 quarters · filed 2025-08-07
248.82K shares
derived: sum of 4 quarters · filed 2025-08-07
2025-03-31134.49K shares
10-Q · filed 2025-05-14
134.49K shares
derived: sum of 2 quarters · filed 2025-05-14
134.49K shares
derived: sum of 3 quarters · filed 2025-05-14
259.22K shares
derived: sum of 4 quarters · filed 2025-05-14
2024-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
0.00 shares
derived: sum of 2 quarters · filed 2025-02-28
124.73K shares
derived: sum of 3 quarters · filed 2025-02-28
179.90K shares
10-K · filed 2025-02-28
2024-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
124.73K shares
derived: sum of 2 quarters · filed 2024-11-07
179.90K shares
10-Q · filed 2024-11-07
275.94K shares
derived: sum of 4 quarters · filed 2024-11-07
2024-06-30124.73K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
179.90K shares
10-Q · filed 2024-08-01
275.94K shares
derived: sum of 3 quarters · filed 2024-08-01
2024-03-3155.16K shares
10-Q · filed 2024-05-02
151.21K shares
derived: sum of 2 quarters · filed 2024-05-02
2023-12-3196.04K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07
100.84K shares
10-K · filed 2024-03-07
2023-09-304.80K shares
10-Q · filed 2023-11-03
2020-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
75.84K shares
10-Q · filed 2020-11-05
2020-06-3075.84K shares
10-Q · filed 2020-08-06
2016-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14
0.00 shares
derived: sum of 2 quarters · filed 2016-11-14
0.00 shares
10-Q · filed 2016-11-14
2016-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10
0.00 shares
10-Q · filed 2016-08-10
2016-03-310.00 shares
10-Q · filed 2016-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
iBio, Inc. (IBIO)United States$0.077B-2.94
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30